Septic ShockSepsisO2CO2RNCT07096284
The PvCO2-PaCO2/CaO2-CvO2 Ratio in Septic Shock
An observational study of Septic Shock, run by Avicenna Military Hospital at 3 sites in Morocco.
Trial summary
The ratio of the venous-arterial carbon dioxide partial pressure difference to the arteriovenous oxygen content difference (Pv-aCO₂/Ca-vO₂) may be a marker of anaerobic metabolism in patients with acute circulatory failure. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Septic Shock
- What is being tested?
- PvCO2-PaCO2/CaO2-CvO2 ratio
- How many people
- 30 participants
- Where
- 3 sitesMorocco
- Study dates
- 5 Jan 2025to 30 Jun 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients aged over 18 years presenting with septic shock, defined as sepsis with persistent hypotension requiring vasopressors to maintain a mean arterial pressure (MAP) ≥ 65 mmHg and lactatemia > 2 mmol/L despite adequate fluid resuscitation. Sepsis is defined by the presence of a suspected or confirmed infectious source associated with organ dysfunction (neurological, respiratory, renal, hepatic, or hematological). [Sepsis 3 criteria]
Who may be able to join
- Patients aged over 18 years presenting with septic shock, defined as sepsis with persistent hypotension requiring vasopressors to maintain a mean arterial pressure (MAP) ≥ 65 mmHg and lactatemia > 2 mmol/L despite adequate fluid resuscitation. Sepsis is defined by the presence of a suspected or confirmed infectious source associated with organ dysfunction (neurological, respiratory, renal, hepatic, or hematological). [Sepsis 3 criteria]
Who cannot join
- Absence of central venous access.
- Central venous access not positioned in the superior vena cava (e.g., femoral access).
Trial locations and contacts
3 sites in 1 country.
Morocco3 sites
Avicenna Military Hospital
Marrakesh, Marrakesh, 40000
Department of critical care Medicine. Avicenna Military Hospital
Marrakesh, Marrakesh, 40000
Avicenna Military Hospital
Marrakesh, 40000
About this study
Official title: Prognostic Value and Kinetics of the PvCO2-PaCO2/CaO2-CvO2 Ratio Compared to Arterial Lactate in the Initial Phase of Septic Shock
The ratio of the venous-arterial carbon dioxide partial pressure difference to the arteriovenous oxygen content difference (Pv-aCO₂/Ca-vO₂) may be a marker of anaerobic metabolism in patients with acute circulatory failure. This study aims to assess the prognostic value of the PvCO2-PaCO2/CaO2-CvO2 in the early phase of septic shock.
Read the detailed description
The ratio of the venous-arterial carbon dioxide partial pressure difference to the arteriovenous oxygen content difference (Pv-aCO₂/Ca-vO₂) may be a marker of anaerobic metabolism in patients with acute circulatory failure. This study aims to compare the kinetics of the PvCO2-PaCO2/CaO2-CvO2 ratio with a classic marker of anaerobic metabolism (arterial lactate) in the early phase of septic shock.
- Conditions
- Septic Shock
- Being tested
- PvCO2-PaCO2/CaO2-CvO2 ratio
- Keywords
- sepsis, anaerobic metabolism
- Medical subject headings
- Shock, Septic, Sepsis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PvCO2-PaCO2/CaO2-CvO2 ratioDiagnostic test
Patients diagnosed with septic shock will undergo serial measurements of arterial and venous blood gas analyses, arterial lactate levels, and calculation of the Pv-aCO₂/Ca-vO₂ ratio at predefined time points: H0 (baseline), H2, H6, H12, and H24.
Calculation Formulas:
- Arterial Oxygen Content (CaO₂):CaO2 = SaO2 × Hb × 1,34 + PaO2 × 0,0031
- Venous Oxygen Content (CvO₂):CvO2 = SvO2 × Hb × 1,34 + PvO2 × 0,0031
- Pv-aCO₂/Ca-vO₂ Ratio: P(v-a) CO2/C(a-v)O2=(PcvCO2-PaCO2)/(CaO2 -CcvO2).
| Study group | Role | What they receive |
|---|---|---|
| Adult patients with septic shock. | Patients aged over 18 years presenting with septic shock. defined as sepsis with persistent hypotension requiring vasopressors to maintain a mean arterial pressure (MAP) ≥ 65 mmHg and lactatemia > 2 mmol/L despite adequate fluid resuscitation. Receives: Diagnostic Test: PvCO2-PaCO2/CaO2-CvO2 ratio |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prognostic value of PvCO2-PaCO2/Ca O2-CvO2 in patients with septic shock
The ability of PvCO2-PaCO2/Ca O2-CvO2 to predict mortality in patients with septic shock. These biological values will be measure using arterial and central venous blood gaz.
Measured: From patient inclusion (baseilie = H0) then at H2, H6, H 12 and H24 (H = hours)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jul 2025
- Study start5 Jan 2025
- Primary completion30 Jun 2026
- Study completion30 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Septic ShockStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- Avicenna Military Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Younes Aissaoui, MD, Avicenna Military Hospital
- Investigators
- Younes Aissaoui Pr, Principal investigator, Cadi Ayyad University. Faculty of Medicine and Pharmacy. Avicenna Military Hospital.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07096284
- Sponsor's protocol ID
- SEPSIS_CO2/O2_vs_lactate
- Acronym
- SepsisO2CO2R
- Status last verified
- Oct 2026
- First submitted
- 26 Dec 2024
- Last updated
- 13 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Biological, hemodynamic and outcome data.
Publications
Ospina-Tascon GA, Madrinan HJ. Combination of O2 and CO2-derived variables to detect tissue hypoxia in the critically ill patient. J Thorac Dis. 2019 Jul;11(Suppl 11):S1544-S1550. doi: 10.21037/jtd.2019.03.52.
PubMed 31388459
Study at a glance
From the registry record, last updated by the sponsor on 13 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prognostic Value and Kinetics of the PvCO2-PaCO2/CaO2-CvO2 Ratio Compared to Arterial Lactate in the Initial Phase of Septic Shock
- ClinicalTrials.gov ID
- NCT07096284
- Acronym / sponsor ID
- SepsisO2CO2R / SEPSIS_CO2/O2_vs_lactate
- Conditions
- Septic Shock
- Keywords
- sepsis, anaerobic metabolism
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- Avicenna Military HospitalUniversity, hospital or other
- Study start
- 5 Jan 2025 (actual)
- Primary completion
- 30 Jun 2026 (actual)
- Study completion
- 30 Jun 2026 (actual)
- First posted
- 31 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The ratio of the venous-arterial carbon dioxide partial pressure difference to the arteriovenous oxygen content difference (Pv-aCO₂/Ca-vO₂) may be a marker of anaerobic metabolism in patients with acute circulatory failure. This study aims to assess the prognostic value of the PvCO2-PaCO2/CaO2-CvO2 in the early phase of septic shock.
Detailed description
The ratio of the venous-arterial carbon dioxide partial pressure difference to the arteriovenous oxygen content difference (Pv-aCO₂/Ca-vO₂) may be a marker of anaerobic metabolism in patients with acute circulatory failure. This study aims to compare the kinetics of the PvCO2-PaCO2/CaO2-CvO2 ratio with a classic marker of anaerobic metabolism (arterial lactate) in the early phase of septic shock.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Adult patients with septic shock. | – | Diagnostic Test: PvCO2-PaCO2/CaO2-CvO2 ratioPatients aged over 18 years presenting with septic shock. defined as sepsis with persistent hypotension requiring vasopressors to maintain a mean arterial pressure (MAP) ≥ 65 mmHg and lactatemia > 2 mmol/L despite adequate fluid resuscitation. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients aged over 18 years presenting with septic shock, defined as sepsis with persistent hypotension requiring vasopressors to maintain a mean arterial pressure (MAP) ≥ 65 mmHg and lactatemia > 2 mmol/L despite adequate fluid resuscitation. Sepsis is defined by the presence of a suspected or confirmed infectious source associated with organ dysfunction (neurological, respiratory, renal, hepatic, or hematological). [Sepsis 3 criteria]
Key inclusion criteria (1 listed)
- Patients aged over 18 years presenting with septic shock, defined as sepsis with persistent hypotension requiring vasopressors to maintain a mean arterial pressure (MAP) ≥ 65 mmHg and lactatemia > 2 mmol/L despite adequate fluid resuscitation. Sepsis is defined by the presence of a suspected or confirmed infectious source associated with organ dysfunction (neurological, respiratory, renal, hepatic, or hematological). [Sepsis 3 criteria]
Key exclusion criteria (2 listed)
- Absence of central venous access.
- Central venous access not positioned in the superior vena cava (e.g., femoral access).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PvCO2-PaCO2/CaO2-CvO2 ratioPatients diagnosed with septic shock will undergo serial measurements of arterial and venous blood gas analyses, arterial lactate levels, and calculation of the Pv-aCO₂/Ca-vO₂ ratio at predefined time points: H0 (baseline), H2, H6, H12, and H24. Calculation Formulas: 1. Arterial Oxygen Content (CaO₂):CaO2 = SaO2 × Hb × 1,34 + PaO2 × 0,0031 2. Venous Oxygen Content (CvO₂):CvO2 = SvO2 × Hb × 1,34 + PvO2 × 0,0031 3. Pv-aCO₂/Ca-vO₂ Ratio: P(v-a) CO2/C(a-v)O2=(PcvCO2-PaCO2)/(CaO2 -CcvO2). | Diagnostic test | Adult patients with septic shock. |
Primary outcome
Prognostic value of PvCO2-PaCO2/Ca O2-CvO2 in patients with septic shock
Time frame: From patient inclusion (baseilie = H0) then at H2, H6, H 12 and H24 (H = hours)
The ability of PvCO2-PaCO2/Ca O2-CvO2 to predict mortality in patients with septic shock. These biological values will be measure using arterial and central venous blood gaz.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Oct 2026.
- Results publication: PubMed 31388459Ospina-Tascon GA, Madrinan HJ. Combination of O2 and CO2-derived variables to detect tissue hypoxia in the critically ill patient. J Thorac Dis. 2019 Jul;11(Suppl 11):S1544-S1550. doi: 10.21037/jtd.2019.03.52.
- Individual participant dataSharing planned: Yes. Biological, hemodynamic and outcome data.
Related trials for Septic Shock
Active, not recruitingPhase 4
Thymosin Alpha 1 and IgM Levels in Sepsis
Sepsis, Septic Shock
Not yet recruiting
Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial
Acute-on-Chronic Liver Failure (ACLF)
Not yet recruiting
ICU-SUCCEED for Survivors of Acute Respiratory Failure and Their Caregivers
Acute Respiratory Failure, Critical Illness
Not yet recruitingObservational study
Longitudinal Trajectories of Myocardial Work in Patients With Sepsis
Sepsis, Septic Shock Hyperdynamic
RecruitingObservational study
Immunothrombosis With Septic Shock Undergoing Renal Replacement Therapy With the OXIRIS Membrane
Sepsis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Younes Aissaoui Pr principal investigator
Cadi Ayyad University. Faculty of Medicine and Pharmacy. Avicenna Military Hospital.
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Septic Shock, run by Avicenna Military Hospital at 3 sites in Morocco.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Morocco. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prognostic value of PvCO2-PaCO2/Ca O2-CvO2 in patients with septic shock (time frame: From patient inclusion (baseilie = H0) then at H2, H6, H 12 and H24 (H = hours)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07096284, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2026.